Premium
Chronic graft‐versus‐host disease and inhibition of interleukin‐17: proof of concept in humans
Author(s) -
Debureaux P.E.,
Masson A.,
Battistella M.,
Fontbrune F.,
Socié G.,
Bouaziz J.D.,
Michonneau D.
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18214
Subject(s) - psoriasis , medicine , interleukin 17 , secukinumab , graft versus host disease , immunology , transplantation , interleukin , hematopoietic stem cell transplantation , cd8 , pathological , disease , cytokine , immune system , pathology , psoriatic arthritis
Summary Psoriasiform chronic graft‐versus‐host disease (Gv HD ) is a rare clinical presentation recently described after allogeneic haematopoietic stem cell transplantation. It is characterized by the combination of clinical and pathological characteristics of psoriasis together with pathological features of chronic Gv HD . As described for psoriasis, psoriasiform chronic Gv HD is characterized by the infiltration of T helper 17 CD 8 + T cells producing both interferon‐γ and interleukin‐17. However, no data are available about the efficacy of interleukin‐17 blockade in the treatment of patients with psoriasiform chronic Gv HD .What's already known about this topic?Psoriasiform chronic graft‐versus‐host disease (GvHD) is a rare clinical presentation with a poor durable response to steroids. Animal models and human data suggest that psoriasiform GvHD could be induced through interleukin‐17 production by donor T cells.What does this study add?We describe the first case of a patient with psoriasiform GvHD and persistent improvement on treatment with secukinumab, an anti‐interleukin‐17A antibody.